Streetbeat News

Stock Prices

RCL

Royal Caribbean Gr (NYSE:RCL) is set to release its quarterly earnings report on July 27, 2023. Analysts estimate an earnings per share (EPS) of $1.55. The company's past performance shows a trend of beating EPS estimates, which has typically resulted in a share price increase. The stock is currently trading at $101.62, up 163.62% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

HOG

Harley-Davidson (NYSE:HOG) is set to release its quarterly earnings report on July 27, 2023. Analysts estimate an earnings per share (EPS) of $1.25. The company's past performance shows it beat the EPS estimate last quarter by $0.65, leading to a 0.92% increase in share price the next day. The stock is currently trading at $37.29 and has seen a 1.03% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

PFE

A large investor has taken a bullish stance on Pfizer (NYSE:PFE), as evidenced by a significant position in the company's options. The sentiment among these big-money traders is split evenly between bullish and bearish. The price target for Pfizer over the last three months, based on volume and open interest, ranges from $20.0 to $40.0. Various financial institutions have given different ratings and price targets for Pfizer.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

DTE

DTE Energy (NYSE:DTE) is set to release its quarterly earnings report on July 27, 2023. Analysts estimate an earnings per share (EPS) of $0.93. The company's past performance shows a mixed impact on the share price post-earnings release. The stock is currently trading at $115.44, down 10.47% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

CROX

Crocs (NASDAQ:CROX) is set to release its quarterly earnings report on 2023-07-27, with analysts estimating an EPS of $2.97. The company's past performance shows a trend of beating EPS estimates. The stock price has seen varied changes post-earnings, with the last quarter witnessing a 0.52% drop despite an earnings beat. The stock is currently trading at $121.87, up 78.61% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

T

A significant amount of bearish options activity has been observed for AT&T (NYSE:T), with 83% of investors opening trades with bearish expectations. The majority of the trades are puts, totaling $934,895, compared to $235,430 in calls. Whales have been targeting a price range from $13.0 to $20.0 for AT&T over the last 3 months. The current price of AT&T is $14.9, up 0.71%. Analysts from Wells Fargo, Citigroup, Deutsche Bank, Barclays, and JP Morgan have maintained their ratings on AT&T, with price targets ranging from $17 to $22.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:02 pm

CBRE

CBRE Group is set to release its quarterly earnings report on July 27, 2023. Analysts estimate an EPS of $0.76. The company's past performance shows a trend of beating EPS estimates, which has generally led to an increase in share price. The stock was trading at $88.11 as of July 25, with a 52-week increase of 4.18%.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:01 pm

EEFT

Euronet Worldwide (NASDAQ:EEFT) has received six analyst ratings in the last quarter, with three being bullish and three indifferent. The average price target is $129.17, indicating an upside from the current price of $93.85. The average price target has increased by 3.01% over the past month.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:01 pm

FOXA

Over the past 3 months, 5 analysts have published their opinion on Fox (NASDAQ:FOXA) stock. The company has an average price target of $35.2, representing a 5.88% decrease from the previous average price target of $37.40. The majority of analysts are indifferent about the stock, with 4 out of 5 giving it a neutral rating.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:01 pm

TARS

HC Wainwright & Co. has maintained its Buy rating for Tarsus Pharmaceuticals (NASDAQ:TARS) and increased its price target from $44.00 to $50.00. Tarsus Pharmaceuticals' shares are trading up 7.79% over the last 24 hours, at $19.44 per share. A move to $50.00 would account for a 157.2% increase from the current share price.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:01 pm